CG
Carl L Gordon (Director) filed 5 Form 4 reports in the trailing twelve months (5 purchases, 0 sales), most often in Electra Therapeutics, Inc. (ETRA). Across 4 priced purchase filings, the average 21-session return was +17.0% from execution and +14.9% from disclosure (delay-adjusted; derived). The largest single filing was $20.0M of ETRA (1,333,333 sh across 2 lots, as filed), executed Sep 21. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+17.0%
avg across 4 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+14.9%
same 4 filings, from disclosure
Filings, ttm
5
5 buys · 0 sells
Median delay
2d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$64.6M
shares × price, as filed
Last traded
Nov 5
Filed Nov 5
Median ADV $26.9M across their filed names
Open performance→Volume by month
Buys $66.7M
Sells $5.7M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
5 filings
Sector per market data · by filing · past 12 months
Most traded names
ETRARecent filings
ETRAPURCHASE
Electra Therapeutics, Inc.
View filing →
$3.5M458,304 sh across 8 lots
Exec Nov 3
Filed Nov 5 · 5:47 PM ET ADRXPURCHASE ADARx Pharmaceuticals, Inc. View filing → $16.1M
950,000 sh across 3 lots
Exec Sep 28
Filed Sep 30 · 5:25 PM ET ETRAPURCHASE Electra Therapeutics, Inc. View filing → $20.0M
1,333,333 sh across 2 lots
Exec Sep 21
Filed Sep 23 · 5:35 PM ET BLSMPURCHASE BlossomHill Therapeutics, Inc. Common Stock View filing → $10.0M
625,000 sh × $16.00
Exec Aug 10
Filed Aug 12 · 4:46 PM ET SCTXPURCHASE Scribe Therapeutics Inc. View filing → $15.0M
1,000,000 sh × $15.00
Exec Jul 27
Filed Jul 29 · 6:50 PM ET CMPXSALE Compass Therapeutics, Inc. View filing → $5.7M
3,571,428 sh × $1.59
Exec Apr 9 2025
Filed Apr 11 2025 · 5:30 PM ET MBXPURCHASE MBX Biosciences, Inc. View filing → $2.0M
190,672 sh across 4 lots
Exec Feb 14 2025
Filed Feb 19 2025 · 5:30 PM ET